Polypill Eligibility for Patients with Heart Failure with Reduced Ejection Fraction in the ASIAN-HF Registry: A Cross-Sectional Analysis.
Polypill Eligibility for Patients with Heart Failure with Reduced Ejection Fraction in the ASIAN-HF Registry: A Cross-Sectional Analysis.
复制标题
作者：
Vijay A;Tay WT;Teng TK;Teramoto K;Tromp J;Ouwerkerk W;Lo SY;Shimizu W;Huffman MD;Lam CSP;Chandramouli C;Agarwal A
在亚洲，射血分数降低的心力衰竭（HFrEF）的指南导向药物治疗（GDMT）处方率仍不理想。本研究的主要目的是在测量亚洲HFrEF受试者中GDMT单个组分的基线处方率的背景下，检查HFrEF复方制剂的合格性。对来自多国ASIAN-HF登记研究的4，868例HFrEF患者进行了回顾性分析，3，716例患者纳入最终完整病例分析。HFrEF复方制剂的合格性（患者根据其进行分组和表征）基于以下内容：左心室收缩功能障碍（基线超声心动图显示LVEF < 40%）、收缩压≥ 100 mm Hg、心率≥ 50次/分钟、eGFR ≥ 30 mL/min/1.73 m和血清钾≤ 5.0 mEq/L。进行回归分析，以评价基线社会人口统计学因素与HFrEF复方制剂合格性的相关性。在ASIAN-HF登记研究的3，716例HFrEF患者中，70.3%有资格接受HFrEF复方制剂。在性别、所有研究地理区域和收入水平中，HFrEF复方制剂合格性显著高于GDMT三联疗法处方的基线率。如果患者是年轻男性，BMI和收缩压较高，则更有可能符合HFrEF复方制剂的条件，如果他们来自日本和泰国，则不太可能符合条件。ASIAN-HF中的大多数HFrEF患者有资格接受HFrEF复方制剂治疗，未接受常规三联治疗。HFrEF多药制剂可能是一种可行且可扩展的实施策略，有助于缩小亚洲HFrEF患者的治疗差距。
The rates of guideline-directed medical therapy (GDMT) prescription for heart failure with reduced ejection fraction (HFrEF) in Asia remain sub-optimal. The primary objective of this study was to examine HFrEF polypill eligibility in the context of measured baseline prescription rates of individual components of GDMT among participants with HFrEF in Asia. A retrospective analysis of 4,868 patients with HFrEF from the multi-national ASIAN-HF registry was performed, and 3,716 patients were included in the final, complete case analysis. Eligibility for a HFrEF polypill, upon which patients were grouped and characterized, was based on the following: left ventricular systolic dysfunction (LVEF < 40% on baseline echocardiography), systolic blood pressure ≥ 100 mm Hg, heart rate ≥ 50 beats/minute, eGFR ≥ 30 mL/min/1.73 m, and serum potassium ≤ 5.0 mEq/L. Regression analyses were performed to evaluate associations of the baseline sociodemographic factors with HFrEF polypill eligibility. Among 3,716 patients with HFrEF in the ASIAN-HF registry, 70.3% were eligible for a HFrEF polypill. HFrEF polypill eligibility was significantly higher than baseline rates of triple therapy prescription of GDMT across sex, all studied geographical regions, and income levels. Patients were more likely to be eligible for a HFrEF polypill if they were younger and male, with higher BMI and systolic blood pressure, and less likely to be eligible if they were from Japan and Thailand. The majority of patients with HFrEF in ASIAN-HF were eligible for a HFrEF polypill and were not receiving conventional triple therapy. HFrEF polypills may be a feasible and scalable implementation strategy to help close the treatment gap among patients with HFrEF in Asia.
登录
查看更多内容
影响因子：
34.3
作者：
Teng, Tiew-Hwa K.;Tromp, Jasper;Lam, Carolyn S. P.
通讯作者：
Lam, Carolyn S. P.
影响因子：
18.2
作者：
Lam, Carolyn S. P.;Anand, Inder;Richards, A. Mark
通讯作者：
Richards, A. Mark
影响因子：
39.3
作者：
Lam, Carolyn S. P.;Teng, Tiew-Hwa Katherine;Richards, A. Mark
通讯作者：
Richards, A. Mark
影响因子：
37.8
作者：
Heidenreich, Paul A.;Bozkurt, Biykem;Yancy, Clyde W.
通讯作者：
Yancy, Clyde W.
影响因子：
168.9
作者：
Santema, Bernadet T.;Ouwerkerk, Wouter;Voors, Adriaan A.
通讯作者：
Voors, Adriaan A.